1-2 of 2
Emily Brooks
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Naval Daver, Joshua F. Zeidner, Junichiro Yuda, Justin M. Watts, Mark J. Levis, Kentaro Fukushima, Takayuki Ikezoe, Yoshiaki Ogawa, Joseph Brandwein, Eunice S. Wang, Yasushi Miyazaki, Timothy Pardee, Naoko Hosono, Takahiro Shima, Hisayuki Yokoyama, Noboru Asada, Joseph Jurcic, Hongliang Cai, Akinobu Watanabe, Matthew Hitron, Emily Brooks, Bo Xu, Jatin Shah, Hagop M. Kantarjian, Harry P. Erba
Journal: Blood
Blood (2023) 142 (Supplement 1): 2911.
https://doi.org/10.1182/blood-2023-179252
Published: 2023
Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, Hongliang Cai, Bo Xu, Jay Stoudemire, Matthew Hitron, Akinobu Watanabe, Philip Komarnitsky, Junichiro Yuda
Journal: Blood
Blood (2022) 140 (Supplement 1): 3371–3372.
https://doi.org/10.1182/blood-2022-167674
Published: 2022